Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Peer-reviewed research, clinical studies, and scientific papers related to eFlow® Technology and inhaled therapies.
Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub.
Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.
Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer.